Clínica Médica

Dengue: importância global, imunopatologia e tratamento.

19 Fev, 2022 | 13:28h

Dengue infection: Global importance, immunopathology and management – Clinical Medicine Journal

Leptospirose: aspectos clínicos.

19 Fev, 2022 | 13:27h

Leptospirosis: clinical aspects – Clinical Medicine Journal

Revisão | Infecções neurológicas tropicais emergentes.

19 Fev, 2022 | 13:26h

Emerging tropical neurological infections – Clinical Medicine Journal

Estudo randomizado | Nirmatrelvir oral para adultos de alto risco com Covid-19 reduz em 89% o risco de internação.

17 Fev, 2022 | 15:37h

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Entrevista em áudio: A New Antiviral against Covid-19 – new England Journal of Medicine

Conteúdos relacionados:

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

Comentário no Twitter

The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c

— Eric Topol (@EricTopol) February 16, 2022

Estudo de coorte | Proteção contra SARS-CoV-2 após vacinação para Covid-19 dura mais em pacientes com infecção prévia.

17 Fev, 2022 | 15:34h

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

Metanálise mostra que a prevalência geral de intolerância à estatina é de cerca de 9% e identifica os fatores de risco mais comuns.

17 Fev, 2022 | 15:31h

Prevalence of statin intolerance: a meta-analysis – European Heart Journal

Comentários:

Study shows the true prevalence of statin intolerance worldwide is between 6 to 10% – News Medical / European Society of Cardiology

Expert reaction to study looking at statin intolerance – Science Media Centre

Conteúdos relacionados:

Side effect patterns in a crossover trial of statin, placebo, and no treatment – This N-of-1 trial, now published in full, suggests the nocebo effect causes most of statins muscle adverse effects.

#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

Comentário no Twitter

Statin intolerance is “over-estimated and over-diagnosed”. World’s largest study shows less than 10% suffer side-effects caused by statins https://t.co/pcVk8YI3I3 @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #Riskfactors pic.twitter.com/b3nFWsc74d

— European Society of Cardiology Journals (@ESC_Journals) February 16, 2022